Last week, the MHRA approved the UK's first oral GLP-1 tablet for weight loss, a semaglutide tablet meeting the regulator's standards for safety, quality and effectiveness. It is the latest in a series of regulatory milestones that have accelerated rapidly in recent years, and it is a timely prompt to look beyond what these medicines can do and ask how they should be delivered. Recent data from leading Diabetes and Obesity meetings has underlined the pace of innovation in the field. Headlines in recent days have been dominated by the next wave of metabolic medicines, including triple agonists, amylin combinations, oral incretins, longer-acting formulations and a widening field of therapies aimed at obesity, type 2 diabetes and cardiometabolic disease. 

For patients and clinicians, this is an encouraging moment. While for industry and health systems, it is also a signal that the market is entering a more complex phase. The question now coming into sharper focus is how these medicines should be used sustainably and effectively in real-world care. 

The next phase of metabolic medicine will therefore require a shift in focus from weight loss to health gain. 

Firstly, greater treatment choice will increase the need for clinical personalisation. Obesity and type 2 diabetes are heterogeneous conditions. Patients differ in biology, comorbidities, treatment history, preferences, risk tolerance and social circumstances. Choice will make infrastructure even more important. As mechanisms, formulations and dosing schedules multiply, the clinical task becomes matching the right patient to the right intervention, at the right dose, with the right level of support and follow-up. 

Secondly, success will need to be measured more broadly. Glucose reduction and weight loss remain important but they are no longer sufficient proxies for success. The field is increasingly focused on cardiovascular risk, kidney protection, liver disease, blood pressure, lipids, sleep apnoea, mobility, quality of life, mental health and long-term function. 

This is an important shift because obesity and type 2 diabetes are chronic, relapsing, multi-system diseases. Treating them as a short course of prescribing misunderstands their biology and underestimates the support patients need. 

Thirdly, real-world adherence is becoming the central challenge. Clinical trials provide structured follow-up, careful titration, intensive monitoring and highly motivated participants. Routine care is different. Patients face side effects, cost barriers, stigma, supply interruptions, competing life pressures and variable access to specialist support. 

Adherence should not be framed simply as a patient behaviour problem; it is a care model problem. Side effects, for example, can often be anticipated and managed. Treatment can be escalated, paused, switched or de-escalated in a planned way. And patients can be monitored for early disengagement.

Finally, AI and digital tools will matter, but as clinical infrastructure. They can help clinicians monitor progress, identify risk, personalise education and support patients between appointments. But technology should not be confused with care. Obesity and diabetes management involves clinical judgement, trust and accountability. Rapid weight loss, gastrointestinal symptoms or disengagement will all require clinical review and consideration, not just automated prompts. The future should therefore be digitally enabled, not digitally delegated. While AI can help scale clinical teams, it should not replace them. 

The GLP-1 era has changed what is possible in metabolic medicine. The next challenge is to change how care is delivered around these therapies. This means moving from episodic prescribing to longitudinal support; from weight loss alone to whole metabolic health; and from isolated interventions to integrated, clinically governed care that delivers long term outcomes.